#1 Clinical Trials Search in Europe

Tolebrutinib

Tolebrutinib is an investigational drug currently being studied in clinical trials for the treatment of multiple sclerosis (MS). As a brain-penetrant Bruton’s tyrosine kinase (BTK) inhibitor, tolebrutinib shows potential in modulating inflammation and slowing disease progression in various forms of MS, including relapsing, primary progressive, and secondary progressive types. This article summarizes key information from ongoing clinical trials evaluating the safety, efficacy, and pharmacokinetics of tolebrutinib in MS patients.

Table of Contents

What is Tolebrutinib?

Tolebrutinib, also known as SAR442168, is a new medication being developed to treat various forms of multiple sclerosis (MS)[1]. It belongs to a class of drugs called Bruton’s tyrosine kinase (BTK) inhibitors. What makes tolebrutinib special is its ability to penetrate the brain, which is crucial for treating MS, a condition that affects the central nervous system[1].

How Tolebrutinib Works

Tolebrutinib works by inhibiting an enzyme called Bruton’s tyrosine kinase (BTK). This enzyme plays a role in the immune system’s response, which is overactive in MS. By blocking BTK, tolebrutinib aims to reduce inflammation in the brain and spinal cord, potentially slowing down the progression of MS[1].

One of the unique features of tolebrutinib is its ability to cross the blood-brain barrier. This barrier normally protects the brain from harmful substances in the blood but can also prevent some medications from reaching the brain. Tolebrutinib’s brain-penetrating ability allows it to directly target inflammation in the central nervous system[1].

Conditions Treated by Tolebrutinib

Tolebrutinib is being studied for several forms of multiple sclerosis, including:

  • Relapsing Multiple Sclerosis (RMS): This is the most common form of MS, characterized by periods of new or worsening symptoms followed by periods of recovery[2].
  • Primary Progressive Multiple Sclerosis (PPMS): In this form, symptoms steadily worsen from the onset of the disease without early relapses or remissions[3].
  • Secondary Progressive Multiple Sclerosis (SPMS): This type initially starts as relapsing MS but later transitions to a progressive form[4].

Clinical Trials and Research

Tolebrutinib is currently undergoing extensive clinical trials to evaluate its effectiveness and safety. Some key studies include:

  • GEMINI 2 Study: This Phase 3 trial is comparing tolebrutinib to teriflunomide (Aubagio), an existing MS medication, in people with relapsing forms of MS[2].
  • HERCULES Study: This study is focusing on the effectiveness of tolebrutinib in people with non-relapsing secondary progressive MS[4].
  • PERSEUS Study: This trial is evaluating tolebrutinib in people with primary progressive MS[3].

These studies are measuring various outcomes, including the rate of relapses, disability progression, and changes in brain lesions as seen on MRI scans[2][4][3].

How Tolebrutinib is Administered

Tolebrutinib is taken orally in the form of a tablet. In most clinical trials, it is being tested at a dose of 60 mg taken once daily[1]. Some studies are also exploring a higher dose of 120 mg daily[1]. The medication is typically taken with food, as this may affect how the body absorbs the drug[5].

Potential Side Effects and Safety

As with any medication, tolebrutinib may cause side effects. The ongoing clinical trials are carefully monitoring participants for any adverse events. Common side effects observed in studies of BTK inhibitors include:

  • Headache
  • Upper respiratory tract infections
  • Diarrhea
  • Fatigue

It’s important to note that the full safety profile of tolebrutinib is still being established through clinical trials[6].

Future Prospects for Tolebrutinib

The development of tolebrutinib represents an exciting advancement in MS treatment. If proven effective and safe in clinical trials, it could offer several advantages:

  • A new option for people who haven’t responded well to existing MS treatments
  • Potential to slow down disease progression in progressive forms of MS, which are currently challenging to treat
  • The convenience of an oral medication that can effectively target inflammation in the brain

Long-term studies are ongoing to assess the safety and effectiveness of tolebrutinib over extended periods[7]. These studies will provide valuable information about the drug’s potential to improve the lives of people with MS in the long run.

Aspect Details
Drug Name Tolebrutinib (SAR442168)
Drug Class Brain-penetrant Bruton’s tyrosine kinase (BTK) inhibitor
Administration Oral tablet, typically once daily
MS Types Studied Relapsing MS, Primary Progressive MS, Secondary Progressive MS
Key Outcome Measures Disability progression, MRI lesions, cognitive function, quality of life
Safety Assessments Adverse events, laboratory tests, ECG, vital signs
Study Durations Ranging from 1 to 5 years, with long-term extension options
Pharmacokinetic Studies Plasma and CSF concentrations, food effect, drug interactions
Biomarkers Neurofilament light chain (NfL), serum immunoglobulins, lymphocyte subsets
Comparators Placebo, teriflunomide (in some studies)

FAQ

  • What is tolebrutinib and how does it work? Tolebrutinib is an investigational drug that acts as a brain-penetrant Bruton's tyrosine kinase (BTK) inhibitor. It works by reducing inflammation in the brain and potentially slowing the progression of multiple sclerosis.
  • What types of multiple sclerosis is tolebrutinib being studied for? Tolebrutinib is being studied for various forms of multiple sclerosis, including relapsing MS, primary progressive MS, and secondary progressive MS.
  • How is tolebrutinib administered? Tolebrutinib is administered orally as a tablet, typically taken once daily.
  • What are some of the main outcomes being measured in tolebrutinib clinical trials? Key outcomes being measured include safety and tolerability, changes in disability progression, effects on brain lesions seen on MRI, cognitive function, and quality of life in MS patients.
  • How long do the clinical trials for tolebrutinib typically last? The duration of tolebrutinib clinical trials varies, but many last between 1 to 5 years, with some studies having long-term extension periods to assess safety and efficacy over time.

Ongoing Clinical Trials on Tolebrutinib

  • Study on Long-Term Safety of Tolebrutinib and Teriflunomide for Patients with Multiple Sclerosis

    Recruiting

    3 1 1
    Investigated diseases:
    Investigated drugs:
    Austria Belgium Bulgaria Croatia Czechia Denmark +17

  • Randomized Study of Tolebrutinib Versus Rituximab in Adults with Multiple Sclerosis

    Not yet recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    Sweden

  • Study on Long-Term Safety of Tolebrutinib for Patients with Relapsing or Progressive Multiple Sclerosis

    Not yet recruiting

    3 1 1
    Investigated diseases:
    Investigated drugs:
    Denmark The Netherlands

  • Study on Tolebrutinib for Patients with Primary Progressive Multiple Sclerosis

    Not recruiting

    3 1
    Investigated diseases:
    Investigated drugs:
    Austria Belgium Bulgaria Croatia Czechia Denmark +13

Glossary

  • Bruton's tyrosine kinase (BTK): An enzyme involved in B-cell development and function, which plays a role in inflammation and is targeted by tolebrutinib to potentially reduce MS disease activity.
  • Relapsing Multiple Sclerosis (RMS): A form of MS characterized by clearly defined attacks of new or increasing neurologic symptoms followed by periods of partial or complete recovery.
  • Primary Progressive Multiple Sclerosis (PPMS): A type of MS where neurologic function worsens continuously from the onset of symptoms, without early relapses or remissions.
  • Secondary Progressive Multiple Sclerosis (SPMS): A phase of MS that follows relapsing-remitting MS, characterized by a progressive worsening of neurologic function over time.
  • Expanded Disability Status Scale (EDSS): A method of quantifying disability in multiple sclerosis and monitoring changes in the level of disability over time.
  • Magnetic Resonance Imaging (MRI): A medical imaging technique used to visualize brain and spinal cord lesions in MS patients.
  • Pharmacokinetics (PK): The study of how a drug is absorbed, distributed, metabolized, and eliminated by the body.
  • Adverse Event (AE): Any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medical treatment or procedure.
  • Cerebrospinal Fluid (CSF): A clear, colorless fluid that surrounds the brain and spinal cord, often analyzed in MS research to measure drug concentrations and biomarkers.
  • Neurofilament Light Chain (NfL): A protein released into the blood and CSF when neurons are damaged, used as a biomarker in MS studies.

References

  1. https://clinicaltrials.gov/study/NCT04742400
  2. https://clinicaltrials.gov/study/NCT04410991
  3. https://clinicaltrials.eu/trial/study-on-tolebrutinib-for-patients-with-primary-progressive-multiple-sclerosis/
  4. https://clinicaltrials.gov/study/NCT04411641
  5. https://clinicaltrials.gov/study/NCT05282030
  6. https://clinicaltrials.gov/study/NCT06372145
  7. https://clinicaltrials.gov/study/NCT03996291